The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus

Prior treatment

• Participate in any drug clinical trials within 3 months;

Other illness

• Allergic to rapamycin or its derivatives；
• Serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients);
• Previous history of cancer or tumor, or pathological examination confirmed precancerous lesions;

Lab values

• The proportion of neutrophils less than 0.5\*10\^9/L or platelet less than 2.5\*10\^10/L;

Other

• Pregnant women or plan to;
• Patients were not optimally managed.

• 18 to 70 years of age;
• Diagnosed as dilated cardiomyopathy. Specifically, (i) left ventricular ejection fraction \<45% (\>2 SD) and/or fractional shortening \<25% (\>2 SD), as ascertained by echocardiography, radionuclide scanning, or cardiac magnetic resonance imaging; (ii) left ventricular end-diastolic diameter \>117% of the predicted value corrected for age and body surface area (Henry's formula), which corresponds to 2 SD of the predicted normal limit +5%; and (iii) In the absence of severe coronary artery disease or valvular disease.
• KSHV DNA seropositivity;
• Patients are voluntary and signed informed consent.